PYC Therapeutics (ASX:PYC) said it continues to progress towards its 48-month objective of becoming a commercial-stage drug developer under its published operational roadmap, according to a Thursday Australian bourse filing.
The focus for the firm now is to generate clinical proof-of-concept for each of its three clinical-stage drug candidates, per the filing.
The company will start with the presentation of phase one and two data for its lead blinding eye disease drug candidate in May, the filing said.
PYC Therapeutics' shares rose almost 6% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.